These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32445720)

  • 21. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
    Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
    J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
    Terasaki D; Smith C; Calcaterra SL
    Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.
    Ober AJ; Murray-Krezan C; Page K; Friedmann PD; Chan Osilla K; Ryzewicz S; Huerta S; Mazer MW; Leamon I; Messineo G; Watkins KE; Nuckols T; Danovitch I
    Addict Sci Clin Pract; 2022 Jul; 17(1):39. PubMed ID: 35902888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
    Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
    JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 28. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 32. The medical management of opioid dependence in HIV primary care settings.
    Lum PJ; Tulsky JP
    Curr HIV/AIDS Rep; 2006 Nov; 3(4):195-204. PubMed ID: 17089480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia.
    Brothers TD; Lewer D; Jones N; Colledge-Frisby S; Farrell M; Hickman M; Webster D; Hayward A; Degenhardt L
    PLoS Med; 2022 Jul; 19(7):e1004049. PubMed ID: 35853024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fulfilling a Need: A Residency-Based Program to Preserve a Suboxone Treatment Program in a Rural Community.
    Buck MC; McCormick AN; Meagher MM; Kauppila G; Witt TJ
    Ann Fam Med; 2021; 19(6):561. PubMed ID: 34750133
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
    Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
    BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Burden of 30-Day Readmissions Associated With Discharge Against Medical Advice Among Inpatients in the United States.
    Kumar N
    Am J Med; 2019 Jun; 132(6):708-717.e4. PubMed ID: 30716295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
    González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
    Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.